Skip to content

Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis

Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07552831
Acronym
T3
Enrollment
64
Registered
2026-04-27
Start date
2026-09-01
Completion date
2038-12-31
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thumb Osteoarthritis

Brief summary

Thumb carpometacarpal osteoarthritis is common and may cause severe pain and functional limitation. Trapeziectomy is widely used, whereas prosthetic arthroplasty may offer faster early recovery. However, detailed information on early postoperative and long-term radiological outcomes remains limited. This is a single-centre, blinded randomised controlled trial at Sahlgrenska University Hospital, Gothenburg, Sweden. Adults aged 18-69 years with symptomatic thumb carpometacarpal osteoarthritis (Eaton grade 2-3) refractory to at least 3 months of non-operative treatment will be randomised 1:1 to trapeziometacarpal prosthetic arthroplasty or trapeziectomy. The primary outcome is day-by-day pain (registration on a numeric rating scale NRS, 0-10). Secondary outcomes include day-by-day analgesic consumption for 90 days, orthosis use after cast removal, patient-reported function (HQ-8, QuickDASH, and Nelson score) at 30, 45, 60, 75 and 90 days, assessor-measured range of motion and strength at 45 and 90 days, and long-term clinical follow-up at 6 months and 1, 2, 5 and 10 years. Cone beam computed tomography will be obtained in the arthroplasty group at 1 week postoperatively as reference and at 6 months and 1, 2, 5 and 10 years to assess implant position, migration and loosening. The target sample size is 64 participants (32 per group), providing 95% power to detect a 1-point between-group difference on the pain scale. Analyses will follow the intention-to-treat principle.

Detailed description

Aim and objectives The primary aim is to compare early postoperative pain trajectories after CMC-1 arthroplasty versus trapeziectomy for symptomatic thumb carpometacarpal osteoarthritis, using day-by-day patient-reported pain measurements during the first 90 postoperative days. Secondary aims are to compare: (i) Daily analgesic consumption during the first 90 postoperative days (ii) Orthosis use after cast removal (iii) Patient-reported hand/upper limb function using HQ-8, QuickDASH and Nelson score (iv) Blinded clinical measures of thumb range of motion, grip strength and pinch strength (v) Long-term clinical outcomes up to 10 years. Additionally, in the arthroplasty group, a long-term aim is to evaluate migration and radiological signs of implant loosening using cone beam computed tomography (CBCT). Similarly, in the trapeziectomy group, CBCT will be used to monitor and quantify metacarpal 1 proximal migration. This protocol has been prepared in accordance with SPIRIT 2025 guidance \[18\], and includes a PRO EDI participant characteristics (Table 1). Trial design This is a single-centre, assessor-blinded randomised controlled trial (RCT) with 1:1 allocation to prosthetic CMC-1 arthroplasty or trapeziectomy. Study setting The study will be conducted at the Hand Surgery Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden. All operations will be performed by surgeons experienced in both techniques at least level 3 according to Giddins-Tang classification \[19\] and have at minimum overcome the previously described learning curve thresholds \[20,21\]. Eligibility criteria Inclusion criteria: * Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or corticosteroid injections). * Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-4. * For Eaton grade 2, age ≥50 years. * Age 18-69 years. * Provision of written informed consent. Exclusion criteria: * Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint). * Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis). * Post-traumatic thumb carpometacarpal osteoarthritis. * Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand. * Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus). * Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty). * Ongoing systemic corticosteroid treatment. * Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis). * Cognitive impairment preventing reliable participation. * Ongoing, or suspected ongoing, alcohol or drug misuse. * Insufficient Swedish language proficiency to complete the questionnaires. Participant identification, recruitment and consent Potential participants will be identified among patients referred for surgical evaluation of symptomatic thumb carpometacarpal osteoarthritis at the study site. Eligible patients will receive verbal and written information about the study. Written informed consent will be obtained before any study-specific data collection. At baseline, participants will complete the HQ-8, QuickDASH and Nelson score questionnaires. Baseline demographic characteristics will be recorded in line with the PRO

Interventions

PROCEDUREtrapeziometacarpal arthroplasty

Participants allocated to arthroplasty will undergo implantation of the Touch® CMC-1 prosthesis according to routine practice at the study site. Surgery will be performed by experienced hand surgeons. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free.

PROCEDURETrapeziectomy

Participants allocated to trapeziectomy will undergo surgical excision of the trapezium without tendon interposition according to routine practice at the study site. Postoperatively, the thumb will be immobilised in a thumb spica cast that leaves the interphalangeal joint free

Sponsors

Sahlgrenska University Hospital
Lead SponsorOTHER
Vastra Gotaland Region
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Masking description

After either intervention, patients will be masked to the hand therapist

Intervention model description

Randomised controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pain at the base of the thumb affecting activities of daily living and insufficient response to at least 3 months of non-operative treatment (orthosis, non-steroidal anti-inflammatory drugs, and/or corticosteroid injections). * Radiographic thumb carpometacarpal osteoarthritis, Eaton grade 2-3. * For Eaton grade 2, age ≥50 years. * Age 18-69 years. * Provision of written informed consent.

Exclusion criteria

* Symptomatic osteoarthritis of adjacent joints (e.g., scaphotrapeziotrapezoid joint, STT-joint). * Need for concurrent surgery in the metacarpophalangeal joint (e.g. arthrodesis or capsulodesis). * Post-traumatic thumb carpometacarpal osteoarthritis. * Previous surgery for thumb carpometacarpal osteoarthritis in the contralateral hand. * Inflammatory arthritis (e.g., rheumatoid arthritis or systemic lupus erythematosus). * Osteoporosis/osteopenia of such severity that secure cup placement in the trapezium is not possible (for arthroplasty). * Ongoing systemic corticosteroid treatment. * Other hand surgical condition in the same hand that could confound outcomes (e.g., carpal tunnel syndrome or de Quervain tenosynovitis). * Cognitive impairment preventing reliable participation. * Ongoing, or suspected ongoing, alcohol or drug misuse. * Insufficient Swedish language proficiency to complete the questionnaires.

Design outcomes

Primary

MeasureTime frameDescription
Pain leveldaily for three monthsPatient-reported pain at the thumb base, measured on a 0-10 numeric rating scale (0 = no pain, 10 = worst imaginable pain).

Secondary

MeasureTime frameDescription
Analgesics useddaily for three monthsDaily registration of analgesic consumption
Use of OrthosisDaily for three months• Orthosis use and perceived importance recorded weekly after cast removal
Patient-reported thumb symptomsat 30, 45, 60, 75 and 90 postoperative daysmeasured with Nelson score (a disease specific questionnaire)
Patient-reported upper extremity functionat 30, 45, 60, 75 and 90 postoperative daysmeasured with QuickDASH questionnaire
Patient-reported hand functionat 30, 45, 60, 75 and 90 postoperative daysmeasured with HQ-8 questionnaire
Range of motionat 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.Objective thumb range of motion (radial and volar abduction) measured by a blinded assessor
Strengthat 45 and 90 postoperative days and at 6 months and 1, 2, 5 and 10 years.Grip strength and pinch strength measured by a blinded assessor
Migration of prosthesis on cone beam computed tomographyat 6 months and 1, 2, 5 and 10 years (with a 1-week reference scan).• Long-term radiological assessment with CBCT in the arthroplasty group to assess implant position, migration and loosening and to assess metacarpal 1 migration in the trapeziectomy group

Contacts

CONTACTJoakim Stromberg, Md,PhD
joakim.stromberg@vgregion.se+46768341327
CONTACTVictoria Wängberg, MD
victoria.wangberg@vgregion.se+46739804631
PRINCIPAL_INVESTIGATORJoakim Stromberg, MD, PhD

Sahlgrenska University Hospital, University of Gothenburg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026